Bio-Techne Licenses AI-Designed NovoBody Duo Molecules From Monod Bio

MT Newswires Live

Nov 18, 2025

Bio-Techne (TECH) said Tuesday it signed a licensing agreement with Monod Bio for exclusive commercial rights to a subset of NovoBody Duo molecules, a new class of AI-designed bispecific binding proteins.

NovoBody Duo molecules are designed to provide multi-specific binding capabilities for advanced research and diagnostic applications, the company said.

The agreement expands Bio-Techne's protein portfolio to support discovery of new biological insights and development of advanced therapeutics, the company said.

Financial terms of the agreement were not disclosed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2584937956"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584937956\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584937956?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 20:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584937956","market":"sh","top_or_hot":-1,"title":"Bio-Techne Licenses AI-Designed NovoBody Duo Molecules From Monod Bio","media":"MT Newswires Live","content":"<html><body><p> Bio-Techne (TECH) said Tuesday it signed a licensing agreement with Monod Bio for exclusive commercial rights to a subset of NovoBody Duo molecules, a new class of AI-designed bispecific binding proteins.</p><p>NovoBody Duo molecules are designed to provide multi-specific binding capabilities for advanced research and diagnostic applications, the company said.</p><p>The agreement expands Bio-Techne's protein portfolio to support discovery of new biological insights and development of advanced therapeutics, the company said.</p><p>Financial terms of the agreement were not disclosed.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Techne Licenses AI-Designed NovoBody Duo Molecules From Monod Bio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Techne Licenses AI-Designed NovoBody Duo Molecules From Monod Bio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-18 20:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Bio-Techne (TECH) said Tuesday it signed a licensing agreement with Monod Bio for exclusive commercial rights to a subset of NovoBody Duo molecules, a new class of AI-designed bispecific binding proteins.</p><p>NovoBody Duo molecules are designed to provide multi-specific binding capabilities for advanced research and diagnostic applications, the company said.</p><p>The agreement expands Bio-Techne's protein portfolio to support discovery of new biological insights and development of advanced therapeutics, the company said.</p><p>Financial terms of the agreement were not disclosed.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0034390439.USD","symbol_name":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2584937956","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584937956","pubTimestamp":1763470760,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Bio-Techne  said Tuesday it signed a licensing agreement with Monod Bio for exclusive commercial rights to a subset of NovoBody Duo molecules, a new class of AI-designed bispecific binding proteins.NovoBody Duo molecules are designed to provide multi-specific binding capabilities for advanced research and diagnostic applications, the company said.The agreement expands Bio-Techne's protein portfolio to support discovery of new biological insights and development of advanced therapeutics, the company said.Financial terms of the agreement were not disclosed.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","BK4588":"碎股","TECH":"Techne Corporation","BK4121":"生命科学工具和服务","BK4585":"ETF&股票定投概念","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","TECH.AU":"GLOBAL X MORNINGSTAR GLOBAL"},"translate_title":"Bio-Techne从Monod Bio获得人工智能设计的NovoBody Duo分子许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH.AU":1,"TECH":1.5},"content_text":"Bio-Techne (TECH) said Tuesday it signed a licensing agreement with Monod Bio for exclusive commercial rights to a subset of NovoBody Duo molecules, a new class of AI-designed bispecific binding proteins.NovoBody Duo molecules are designed to provide multi-specific binding capabilities for advanced research and diagnostic applications, the company said.The agreement expands Bio-Techne's protein portfolio to support discovery of new biological insights and development of advanced therapeutics, the company said.Financial terms of the agreement were not disclosed.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}